

At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant

1

2 Nagendrakumar B Singanallur^{1†}, Petrus Jansen van Vuren^{1†}, Alexander J McAuley^{1†}, Matthew
3 P Bruce¹, Michael J Kuiper², Stella M Gwini³, Shane Riddell¹, Sarah Goldie¹, Trevor W Drew¹,
4 Kim R Blasdell¹, Mary Tachedjian¹, Shruthi Mangalaganesh^{1,4}, Simran Chahal¹, Leon Caly⁵,
5 Julian D Druce⁵, Jennifer A Juno⁶, Stephen J Kent⁶, Adam K Wheatley⁶, Seshadri S Vasan^{1,7*}

6 ¹Commonwealth Scientific and Industrial Research Organisation (CSIRO) Australian Centre for
7 Disease Preparedness (ACDP), Geelong, VIC 3220, Australia

8 ²Data61, Commonwealth Scientific and Industrial Research Organisation (CSIRO), Docklands, VIC
9 3008, Australia

10 ³University Hospital Geelong, Barwon Health, Geelong, VIC 3220, Australia

11 ⁴Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC 3168, Australia

12 ⁵Victorian Infectious Diseases Reference Laboratory (VIDRL), The Peter Doherty Institute for
13 Infection and Immunity, Melbourne, VIC 3000, Australia

14 ⁶Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty
15 Institute for Infection and Immunity, Melbourne, VIC 3000, Australia

16 ⁷Department of Health Sciences, University of York, York, YO10 5DD, United Kingdom

17 [†]These authors have contributed equally to this work and share first authorship

18 *Correspondence:

19 Prof. Seshadri S. Vasan, vasan.vasan@csiro.au; orcid.org/0000-0002-7326-3210

20 Abstract

21 Plasma samples taken at different time points from donors who received either AstraZeneca
22 (Vaxzevria) or Pfizer (Comirnaty) or Moderna (Spikevax) coronavirus disease-19 (COVID-19)
23 vaccine were assessed in virus neutralization assays against Delta and Omicron variants of concern
24 and a reference isolate (VIC31). With the Pfizer vaccine there was 6-8-fold reduction in 50%
25 neutralizing antibody titres (NT₅₀) against Delta and VIC31 at 6 months compared to 2 weeks after
26 the second dose; followed by 25-fold increase at 2 weeks after the third dose. Neutralisation of
27 Omicron was only consistently observed 2 weeks after the third dose, with most samples having titres
28 below the limit of detection at earlier timepoints. Moderna results were similar to Pfizer at 2 weeks
29 after the second dose, while the titres for AstraZeneca samples derived from older donors were 7-fold
30 lower against VIC31 and below the limit of detection against Delta and Omicron. Age and gender
31 were not found to significantly impact our results. These findings indicate that vaccine matching may
32 be needed, and that at least a third dose of these vaccines is necessary to generate sufficient
33 neutralising antibodies against emerging variants of concern, especially Omicron, amidst the
34 challenges of ensuring vaccine equity worldwide.

35 **Keywords:** AlphaFold; BA.1.1; biomolecular modelling; COVID-19; neutralising antibody
36 titres; SARS-CoV-2; Spike protein; variants of concern; vaccines; vaccine matching

37 Introduction

Neutralization of SARS-CoV-2 Omicron

38 The novel coronavirus disease-19 (COVID-19) pandemic caused by the severe acute
39 respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in over half a billion cases and 6.2
40 million deaths, and is yet to be brought under control [1]. Only 14.2 vaccine doses have been
41 administered per 100 people in ‘low-income countries’; for ‘lower middle income countries’
42 excluding India the number is 81.6 doses per 100 people [2]. Thus, half the world’s population is still
43 receiving the first dose of a COVID-19 vaccine and is very vulnerable [3]. Although vaccines can
44 reduce the likelihood of infection, re-infection and disease severity in individuals, and to an extent
45 community transmission, the continuous emergence of SARS-CoV-2 variants of concern (VOC) has
46 frustrated global response efforts and highlighted the importance of continued assessment of vaccine
47 efficacy [4,5]. The World Health Organization has declared 5 VOC to date, viz. Alpha (18 December
48 2020), Beta (18 December 2020), Gamma (11 January 2021), Delta (11 May 2021), Omicron (26
49 November 2021), of which Delta and Omicron are currently of the greatest concern and two variants
50 of interest (VOI) viz. Lambda (14 June 2021) and Mu (30 August 2021) [6].

51 While studies on T-cell responses will provide a more holistic picture of vaccine-induced
52 efficacy, assessment of neutralising antibody reactivity against emerging VOC, such as Omicron
53 (B.1.1.529, referred to as BA.1 henceforth), can help inform near-term public health response. This is
54 especially important for the vaccines manufactured by Pfizer, Moderna, and AstraZeneca, as one or
55 more of these three are approved in 192 countries (which does not include the People’s Republic of
56 China), representing 77% of the world’s population [2]. In this study we have assessed the ability of
57 human plasma samples collected from vaccinated donors at different timepoints to neutralise
58 infectious SARS-CoV-2 virus isolates of the current two most globally-prevalent VOC (Delta and
59 Omicron; particularly the under-studied Omicron BA.1.1 sub-lineage) compared with a reference
60 isolate used in previous studies (VIC31; [7]). This adds to the collective evidence base of the efficacy
61 of existing vaccines against the Omicron VOC (of which there are a number of sub-lineages), from
62 the perspective of different experimental protocols (including cell lines) and regional patient and
63 virus samples [4,5]. We have further bolstered our interpretation using *in silico* modelling of the
64 respective Spike proteins and outlined our thoughts on future follow-up studies.

65 **Materials and Methods**

66 **SARS-CoV-2 Stock Generation and Characterisation**

67 Three SARS-CoV-2 isolates, VIC31 (B.1; hCoV-19/Australia/VIC31/2020 containing D614G
68 mutation), Delta (B.1.617.2) variant of concern (hCoV-19/Australia/VIC18440/2021), and Omicron
69 (BA.1.1) variant of concern (hCoV-19/Australia/VIC28585/2021) were provided by the Victorian
70 Infectious Diseases Reference Laboratory (VIDRL; Melbourne, Australia). Virus stocks were
71 propagated and titrated in Vero E6 cells (American Type Culture Collection (ATCC), Manassas, VA,
72 USA) prior to use as previously outlined in [8]. Briefly, Vero E6 cells were grown in 150 cm² flasks
73 in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% heat-inactivated foetal bovine
74 serum (FBS), 2mM GlutaMAX supplement, 100U/mL penicillin, and 100 µg/mL streptomycin (all
75 components from ThermoFisher Scientific; Scoresby, VIC, Australia) until >80% confluent. Virus
76 isolates were diluted 1:100 in DMEM (containing 2% FBS, 2mM GlutaMAX supplement, 100U/mL
77 penicillin, and 100 µg/mL streptomycin), and 5 mL was used to inoculate Vero E6 cells for 1 hr at
78 37°C/5% CO₂ before additional media was added to the flask. The flasks were incubated at 37°C/5%
79 CO₂ for 48 h (for VIC31 and Delta) or 72 hr (for Omicron) before supernatant was clarified at 2,000
80 x g for 10 min, and harvested and stored in 1 mL aliquots at -80°C.

Neutralization of SARS-CoV-2 Omicron

81 Identity of virus stocks were confirmed by next-generation sequencing using a MiniSeq
82 platform (Illumina, Inc; San Diego, CA, USA). In brief, 100 μ L cell culture supernatant from
83 infected Vero E6 cells was combined with 300 μ L TRIzol reagent (Thermo Fisher Scientific) and
84 RNA was purified using a Direct-zol RNA Miniprep kit (Zymo Research; Irvine, CA, USA). Purified
85 RNA was further concentrated using an RNA Clean-and-Concentrator kit (Zymo Research), followed
86 by quantification on a DeNovix DS-11 FX Fluorometer. RNA was converted to double-stranded
87 cDNA, ligated then isothermally amplified using a QIAseq FX single cell RNA library kit (Qiagen,
88 Hilden, Germany). Fragmentation and dual-index library preparation was conducted with an Illumina
89 DNA Prep, Tagmentation Library Preparation kit. Average library size was determined using a
90 Bioanalyser (Agilent Technologies; San Diego, CA, USA) and quantified with a Qubit 3.0
91 Fluorometer (Invitrogen; Carlsbad, CA, USA). Denatured libraries were sequenced on an Illumina
92 MiniSeq using a 300-cycle Mid-Output Reagent kit as per the manufacturer's protocol. Paired-end
93 Fastq reads were trimmed for quality and mapped to the published sequence for the SARS-CoV-2
94 reference isolate Wuhan-Hu-1 (RefSeq: NC_045512.2) using CLC Genomics Workbench version 21
95 from which consensus sequences were generated. Stocks were confirmed to be free from
96 contamination by adventitious agents by analysis of reads that did not map to SARS-CoV-2 or cell-
97 derived sequences.

98 **Human Plasma Samples**

99 Blood samples in EDTA blood collection tubes (BD Biosciences, Australia) were collected
100 from healthy volunteers, aged between 25-70 (both female and male), who received COVID-19
101 vaccine manufactured by either AstraZeneca (Vaxzevria/AZD1222; University of Oxford-
102 AstraZeneca, Oxford/Cambridge, UK), Pfizer (Comirnaty/BNT162b2; BioNTech-Pfizer, Brooklyn,
103 New York, USA), or Moderna (Spikevax/mRNA-1273; Moderna Inc, Cambridge, MA, USA) (**Table**
104 **1**). AstraZeneca vaccine was advised for the age group >60 [9]. All groups received the same vaccine
105 (homologous) for first and second doses. Most of the Pfizer vaccine group also received a third dose
106 as homologous booster, while the groups that received AstraZeneca or Moderna did not post-third
107 dose samples available. Plasma was separated and stored at -70°C until use. The study protocols
108 were approved by institutional ethics committees of the Peter Doherty Institute, Melbourne Australia
109 [University of Melbourne Central Human Research Ethics Committee (2021-21198-15398-3)] and
110 the CSIRO (CSIRO Human Research Ethics Committee ID 2021_123_RR). Biosafety protocols for
111 handling the human samples and the infectious agents were approved by the Institutional Biosafety
112 Committee of ACDP, Geelong before infectious work commenced. Blood samples were collected on
113 the day of vaccination (baseline; pre-1st dose) and 2 weeks post second dose (2wk-2nd dose) for all
114 the vaccine groups and after six months of 2nd dose (6mo-2nd dose) and two weeks post third dose
115 (2wk-3rd dose) for the Pfizer group.

116 **Live-Virus Neutralisation Assays**

117 Virus neutralization assays (VNT) were carried out using Vero E6 cells as described previously
118 [8]. Briefly, each plasma sample for the three vaccines was diluted 1:10 in Dulbecco's Phosphate
119 Buffered Saline (DPBS; Thermo Fisher Scientific, Waltham, MA, USA) in a deep-well plate,
120 followed by a two-fold serial dilution up to 1:1,280. The dilution series for each plasma sample was
121 dispensed into triplicate columns of a 96-well plate (one plate per isolate), for a total volume of 50 μ l
122 per well. For the plasma-containing wells, 50 μ l virus diluted in DMEM (Thermo Fisher Scientific,
123 Waltham, MA, USA) containing 2% FBS, 2mM GlutaMAX supplement, 100U/mL penicillin, and
124 100 μ g/mL streptomycin to contain approximately 100 TCID₅₀ (checked by back-titration) was added
125 to each well. The plates were incubated at 37°C/5% CO₂ for 1 h to allow neutralization complexes to

Neutralization of SARS-CoV-2 Omicron

126 form between the antibodies present in the plasma and the virus. A positive control serum was
127 included to confirm the reproducibility of the assay. At the end of the incubation, 100 μ l Vero E6
128 cells (2×10^4 cells/well) were added to each well and the plates were returned to the incubator for 4
129 days. Each well was scored for the presence of viral CPE, readily discernible on Day 4 post-infection.
130 NT_{50} neutralization titres calculated using the Spearman–Kärber formula [10] and transformed to \log_2
131 values for analysis. Replicates that did not show neutralisation at 1:10 were scored <1:10 dilution and
132 assigned a value 1:5 for statistical analysis in line with the current best practice [11].

133 *In silico* Modelling

134 Molecular models were made of the trimeric Omicron Spike protein from residues 13 to 1160
135 (omitting the transmembrane domain) consistent with variant BA.1.1 and including glycosylation to
136 visualize structural changes from the original strain. ‘AlphaFold’ [12] was used to reconstruct the N-
137 terminal domain due to insertions and deletions. Models were built to include the ‘up’ and ‘down’
138 conformations of the Receptor Binding Domain (RBD, residues 330-530) as well as the human
139 angiotensin converting enzyme 2 (ACE2) receptor. Building upon our previous work [13], models
140 were solvated and simulated using ‘NAMDv2.14’ software [14] for over 200 nanoseconds before
141 visual assessment of changes to surface epitopes and receptor binding interfaces. More modelling
142 details included in Supplementary Methods.

143 Statistical Analysis

144 NT_{50} values were analysed and expressed as Log base 2 (\log_2). The VNT data were grouped
145 based on vaccines, sex (female and male), and age groups (<35 – young; 35-60 – middle and >60 –
146 senior). Both one-way and two-way Analysis of Variance (ANOVA) were used to test the statistical
147 differences between vaccines, sex, age, day post vaccination/booster, variants, and their interactions.
148 If the ANOVA results returned a p-value of <0.05, a *post hoc* test with a Tukey’s range test (Tukey’s
149 Honestly Significant Difference, c.f. Supplementary Tables) was performed to measure the
150 interactions between two variables. Plots were drawn using ‘ggplot2’ and modified in Adobe
151 Illustrator for clarity. All statistical procedures used the ‘car’ and ‘lme4’ libraries in R [15]. Fold
152 changes were calculated as: $2^{(\log_2 x - \log_2 y)}$.

153 Results and Discussion

154 Neutralisation of Delta and Omicron Variants of Concern

155 As neutralising antibody titres are a known correlate of protection for SARS-CoV-2 [16],
156 neutralisation assays were performed against SARS-CoV-2 VIC31, Delta, and Omicron using plasma
157 samples collected from human volunteers. **Table 1** shows the median ages for AstraZeneca sample
158 donors are 57.5 compared to 38.5 for Moderna, and 33 for Pfizer vaccine donors respectively, the
159 reasons for which are as follows. The Australian Technical Advisory Group on Immunisation
160 (ATAGI) changed its recommendations regarding the AstraZeneca vaccine following reports of
161 thrombotic thrombocytopenia syndrome (TTS) emerging from vaccinated adults [17]. It is worth
162 noting that some individuals younger than 60 have received AstraZeneca vaccine following an
163 assessment by a qualified health professional and with a verbal or written consent as provisioned by
164 the Department Health, Government of Australia [9], but there is no brand preference for people aged
165 60 years and above because the benefits outweigh the risk of TTS in this age group. As a result,
166 samples predominantly originated from young and middle-aged individuals for the Moderna and
167 Pfizer vaccines, and from middle-aged and senior adults for the AstraZeneca vaccine. Given the large

Neutralization of SARS-CoV-2 Omicron

168 age range for the Pfizer vaccine, for this manuscript we classified the age groups in to young (<35
169 age), middle (35-60) and senior (>60). We chose 35 as the cut-off for middle age as it generally
170 corresponds to parents of teen aged children and is used in metrics such as the Peterson-KFF health
171 System Tracker [18] which has identified COVID-19 as the second and third most important cause of
172 death of people who are over and under 35, respectively. In Australia, Moderna vaccine was
173 approved for use relatively recently (9 August 2021), while a third dose of the AstraZeneca is only
174 approved in exceptional circumstances, therefore this study did not have access to third-dose samples
175 for these vaccines.

176 Calculation of fold changes using the data presented in **Table 2** and **Figure 1**, demonstrate that
177 for the Pfizer vaccine there was an 8.2- and 5.5-fold reduction in NT₅₀ titres against VIC31 and Delta
178 respectively 6 months after second dose administration (compared to two weeks), while the average
179 titre against Omicron decreased from an estimated 1:6.3 (only 4/15 samples had quantifiable
180 neutralization) to below assay detection limit for all samples at the same time points, demonstrating
181 that levels of circulating neutralising antibodies decrease in the months following vaccination.
182 Subsequently there was a 25.5- and 24.6-fold increase in titres against VIC31 and Delta respectively
183 two weeks after a third dose administration (compared to 6 month post-second dose), while the
184 average titre against Omicron increased from below assay detection limit to 1:48.5 at the same time
185 points. Because of the aforementioned limitations, calculation of such fold changes for AstraZeneca
186 and Moderna were not possible. However, it is worthwhile to compare their neutralisation titres two
187 weeks post-second dose relative to the Pfizer vaccine samples. Across all three variants, we did not
188 find any significant difference between Pfizer and Moderna vaccines by 2nd week post second dose of
189 the vaccines (**Supplementary Table S1**). Interestingly, the neutralisation titres against VIC31 were
190 generally lower than have been reported in other studies with equivalent samples and virus isolates.
191 This is likely a reflection of the protocol and cells used in this study, and the age groups/populations
192 from which the samples were collected [4].

193 ANOVA (one-way and two-way) was used to investigate the interactions of age, sex, vaccine,
194 and day post vaccination/booster with neutralising antibody titres to the three different virus variants.
195 One-way and two-way ANOVA analyses showed that, for all vaccines (Pfizer, Moderna and
196 AstraZeneca), day post vaccination/booster and virus variant were the main contributors to
197 differences in neutralising antibody responses, while age and sex did not have significant effects.
198 Based on ANOVA analysis there was no significant difference in neutralising titres based on age or
199 sex for any of the vaccines (**Supplementary Tables S2 & S3; Figure 2A-C**). The titres were
200 dependent on the vaccine, day post-vaccination and variant ($p < 0.001$) and to an extent the age where
201 antibody titres in young showed statistically significant difference when 2nd compared to the middle and
202 senior age groups ($p = 0.022$). The antibody titres against Omicron have a negative slope and
203 indicating that there is poor neutralisation with the variant.

204 **Importance of Third Dose for Neutralisation of Omicron**

205 In line with recent findings in similar studies by other groups [19,20], Omicron titres were
206 significantly lower than VIC31-D614G and Delta titres at all time points and regardless of vaccine,
207 highlighting the concern of poor protection to Omicron following vaccination by any of the three
208 leading vaccines. One shortcoming of our data is the lack of later samples and post-boost (third
209 vaccination) from individuals vaccinated with AstraZeneca and Moderna vaccines. However, the data
210 available from Pfizer vaccinated individuals at 6 months after receiving their second dose indicate a
211 significant waning of immunity to all three variants over this period. Neutralising antibody levels to
212 Omicron were low or undetectable in most individuals two weeks after receiving two Pfizer doses,

Neutralization of SARS-CoV-2 Omicron

213 and below the assay limit of detection in all samples tested at 6 months after the second dose.
214 However, at two weeks after the booster vaccination (third Pfizer dose), a significant booster effect in
215 neutralising titres was noted to all three variants. This highlights the importance of the need for a
216 booster (third) vaccine dose for ongoing protection against D614G and Delta variants, but more
217 importantly that two doses are insufficient to stimulate significant neutralising protection against
218 Omicron BA.1, therefore making the third dose essential. The cause of better protection against
219 Omicron BA.1 following three doses of vaccine incorporating Spike protein lacking Omicron
220 specific mutations, is likely due to higher overall neutralising titres due to a booster effect despite
221 neutralising antibodies to certain epitopes being circumvented.

222 **Modelling and Analyses using *in silico* methods**

223 In order to identify a mechanistic explanation for the observed reduction in neutralisation of
224 Omicron compared to other variants, we investigated the amino acid mutations present in Omicron.
225 Consistent with other studies, there are significantly more mutations in the Spike protein of the
226 Omicron variant shown in **Figure 4A**, (37 mutations in the BA.1 variant, 32 in the BA.2 variant
227 including insertions and deletions), compared to the Delta variant (10 mutations), while only one in
228 the VIC31 strain (D614G). The Omicron mutations contribute to its ability to circumvent vaccine or
229 infection induced neutralising antibody responses [19,20]. Three of these mutations (G142D, T478K
230 and D614G) are common to Delta and Omicron, however we have previously shown experimentally
231 and through *in silico* modelling that D614G has no significant impact on vaccines [7]. In the receptor
232 binding domain (RBD) of the Spike protein alone, which is most immunologically exposed in its ‘up’
233 configuration and critical for ACE2 binding, there are 15 and 17 mutations in the Omicron BA.1 and
234 BA.2 variants compared to only 2 in Delta as shown in **Figures 4A & C**. Many of the observed
235 Omicron mutations by our analysis appear to be immune evasive, as they do not appear to be at the
236 ACE2 binding interface and represent a significant change in the residue characteristics; in the RBD,
237 these include N440K, K417N, S477N, T478K, and E484A.

238 Interestingly our isolate VIC28585 belongs to the BA.1.1 sub-lineage as it also contains the
239 R346K spike mutation, which possibly further decreases antibody neutralization based on the
240 reduced binding of class 2 antibodies in theoretical studies with the Mu variant of interest [21]. Next-
241 generation sequencing results also indicated the presence of additional Spike mutations S373P and
242 S375F in our VIC28585 isolate at frequency exceeding 99.8%; these two mutations with Grantham
243 scores of 74 (moderately conservative change) and 155 (radical change) respectively are near the
244 S371L Spike mutation characteristic to BA.1 which has a Grantham score of 145 (moderately radical
245 change; *n.b.* these three mutations are also present in EPI_ISL_7869197 mentioned below). Thus, we
246 have investigated the neutralising responses to Omicron BA.1.1 in individuals vaccinated with three
247 leading COVID-19 vaccines and compared these neutralising titres to those against an early SARS-
248 CoV-2 isolate with the D614G mutation (VIC31), and the Delta variant (B.1.617.2) that subsequently
249 became the dominant variant worldwide prior to Omicron’s emergence. For example, on 11
250 December 2021 the ratio of Delta : BA.1 : BA.1.1 : BA.2 : Other in USA (where extensive data is
251 available from the CDC; [22]) was 92.5 : 5.2 : 2.2 : 0 : 0.2, and this steadily changed over two
252 months so that on 12 February 2021 the ratio was 0 : 22.9 : 73.2 : 3.9 : 0. This shows that BA.1.1,
253 used in our study, could emerge as the dominant variant although we need to wait for more
254 comprehensive data from around the world – as of 16 February 2022, 719,364 sequences of BA.1
255 were reported from 139 countries, while 410,015 sequences of BA.1.1 were reported from 127
256 countries.

Neutralization of SARS-CoV-2 Omicron

257 Other Omicron mutations are likely to confer increased binding affinity to ACE2 by increasing
258 molecular interactions such as salt bridges and pi-stacking [12]; these mutations include Q493R and
259 Q498R (increasing salt bridge interactions with ACE2's D38 and E35) and N501Y (also seen in
260 Alpha, Beta and Gamma variants, pi-stacking with ACE2's Y41, shown in **Supplementary Figure**
261 **S1**. A cluster of mutations S371L, S373P and S375F, interestingly appear co-located with Y505H in
262 adjacent RBD domains in the 'down' position. These serine mutations, as well as significantly
263 altering epitope presentation of the RBD domain by creating a more rigid structural motif, may allow
264 H505 to interact with the adjacent F375, potentially modulating 'up'/'down' conformations via the
265 ionizable H505, (pK_a of 6.0). This structural change may coincide with the observed Omicron
266 preference of infection to the bronchus, where pH is usually lower at 5.5 to 6.5, compared to the lung
267 [23,24] (**Supplementary Figure S2**).

268 With the large number of mutations, it is unsurprising that the Omicron variant displays the
269 observed antibody evasion and replicative advantage over earlier variants as seen in other studies and
270 experimentally observed in this study [3,25]. Our biomolecular modelling shows sufficient
271 distinction between BA.1 and BA.2, therefore future studies should experimentally compare the two.

272 **Public Health Implications and Future Studies**

273 The data we present here highlight the importance of booster vaccination for adequate
274 protection against newly emerging variants such as Omicron BA.1.1, particularly the observation that
275 two doses of the three leading vaccines are not sufficient for neutralisation of Omicron, while a third
276 dose of Pfizer resulted in detectable neutralisation titres in all donor samples. Further studies are
277 needed to perform similar analyses of neutralising titres in individuals receiving "heterologous"
278 booster doses, e.g., initial AstraZeneca vaccination followed by Moderna or Pfizer boost, or Pfizer-
279 Moderna / Moderna-Pfizer.

280 In the early days of the pandemic, the scientific prediction was that SARS-CoV-2 will have a
281 mutation rate similar to SARS-CoV ($0.8-2.4 \times 10^{-3}$) thanks to the 3'-to-5' exoribonuclease
282 'proofreading mechanism' in coronaviruses [26], which was thought to result in a reduction in the
283 mutation rate ($\sim 10^{-6}$ per site per cycle) compared to influenza ($\sim 3 \times 10^{-5}$ per site per cycle) [27,28].
284 Therefore, it was predicted that vaccine matching may not be required as frequently as seasonal
285 influenza (once a year each for Northern and Southern hemispheres), although this was hard to say
286 definitively because SARS-CoV-2's genetic drift was uncertain with respect to the long-lasting
287 efficacy of vaccine candidates then under development [29]. Early studies, for instance between 1
288 February to 1 May 2020 seemed to confirm the mutation rate prediction with a median estimate of
289 1.12×10^{-3} per site-year ([30]; we believe their upper 95% confidence interval should read 1.85×10^{-3}).

290 Two years on, we have increasing evidence, including from this work, that the primary
291 immunization schedule should consist of three rather than two doses, and indeed many countries are
292 redefining 'fully vaccinated' status as three doses of these vaccines [31]. It is early to speculate on
293 annual boosters beyond the third dose, although Israel has started to expand its fourth dose
294 administration to groups beyond the immunocompromised [32,33]. These developments make it all
295 the more important to ensure vaccine equity across the world, so everyone is adequately protected
296 and highlight the potential need for vaccine matching to increase protection against infection.
297 Vaccines using Spike as the primary antigen should consider including mutations common to BA.1,
298 BA.1.1, and BA.2; development of vaccines with additional antigens, other than Spike, targeting
299 more conserved viral factors should also be explored. This view is further supported by a recent
300 preprint currently under peer review suggesting that, although a fourth dose restored anti-Omicron

Neutralization of SARS-CoV-2 Omicron

301 BA.1 (EPI_ISL_7869197) neutralising antibody titres to a level observed post-third dose,
302 breakthrough Omicron infections were common with high virus titres, albeit with very mild clinical
303 signs [33,34].

304 In this context, it is important to explore vaccines that can better withstand mutations to the
305 Spike protein better, and ideally have less dependence on cold chain. In addition to repeating this
306 work with Omicron BA.2, it is also important to explore the benefits of T-cell immunity and
307 heterologous boosting (which are beyond the scope of this paper; but see for instance these studies
308 [35-38]). Another aspect worth exploring is intranasal administration of selected vaccines. In the
309 earliest study (conducted from March 2020) looking at intranasal administration of the AstraZeneca
310 vaccine [39], we found that although neutralising antibody titres were 2-fold lower in ferrets
311 receiving two doses of this vaccine intranasally compared to the intramuscular route, the former was
312 more protected using virus shedding as an infection metric [40]. These findings were subsequently
313 confirmed in hamsters and non-human primates [41], and also reportedly led to a small clinical trial
314 in 30 humans [42]. We feel that the intranasal route, and the role of mucosal immunity, needs to be
315 explored more comprehensively given that the AstraZeneca vaccine has the widest reach (183
316 countries worldwide), with over 2.5 billion doses administered [43].

317

318 References

- 319 1. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al.
320 Coronavirus Pandemic (COVID-19) [Internet]. Our World in Data. 2020 [cited 20 February
321 2022]. Available from: <https://ourworldindata.org/coronavirus>
- 322 2. World Bank. *World Bank Country and Lending Groups* (2022). Available at:
323 [https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
324 [lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
- 325 3. Jansen van Vuren, P, McAuley, AJ, Kuiper MJ, Singanallur, NB, Bruce, MP, et al. Highly
326 thermotolerant SARS-CoV-2 vaccine elicits neutralising antibodies against Delta and
327 Omicron in mice. *Viruses* (2022) 14(4): 800. doi: 10.3390/v14040800.
- 328 4. WHO. *What recent evidence do we have that omicron is evading immunity and what are the*
329 *implications?* (2022). Available at: [https://www.who.int/news-](https://www.who.int/news-room/events/detail/2022/02/14/default-calendar/save-the-date---what-recent-evidence-do-we-have-that-omicron-is-evading-immunity-and-what-are-the-implications)
330 [room/events/detail/2022/02/14/default-calendar/save-the-date---what-recent-evidence-do-we-](https://www.who.int/news-room/events/detail/2022/02/14/default-calendar/save-the-date---what-recent-evidence-do-we-have-that-omicron-is-evading-immunity-and-what-are-the-implications)
331 [have-that-omicron-is-evading-immunity-and-what-are-the-implications](https://www.who.int/news-room/events/detail/2022/02/14/default-calendar/save-the-date---what-recent-evidence-do-we-have-that-omicron-is-evading-immunity-and-what-are-the-implications)
- 332 5. WHO. *What evidence do we have that omicron is evading immunity and what are the*
333 *implications?* (2021). Available at: [https://www.who.int/news-](https://www.who.int/news-room/events/detail/2021/12/15/default-calendar/who-global-consultation---what-evidence-do-we-have-that-omicron-is-evading-immunity-and-what-are-the-implications)
334 [room/events/detail/2021/12/15/default-calendar/who-global-consultation---what-evidence-do-](https://www.who.int/news-room/events/detail/2021/12/15/default-calendar/who-global-consultation---what-evidence-do-we-have-that-omicron-is-evading-immunity-and-what-are-the-implications)
335 [we-have-that-omicron-is-evading-immunity-and-what-are-the-implications](https://www.who.int/news-room/events/detail/2021/12/15/default-calendar/who-global-consultation---what-evidence-do-we-have-that-omicron-is-evading-immunity-and-what-are-the-implications)
- 336 6. WHO. *Tracking SARS-CoV-2 variants* (2022). Available at:
337 <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>
- 338 7. McAuley AJ, Kuiper MJ, Durr PA, Bruce MP, Barr J, Todd S, et al. Experimental and in
339 Silico Evidence Suggests Vaccines Are Unlikely to Be Affected by D614G Mutation in
340 SARS-CoV-2 Spike Protein. *npj Vaccines* (2020) 5(1):96. doi: 10.1038/s41541-020-00246-8.
- 341 8. Malladi SK, Patel UR, Rajmani RS, Singh R, Pandey S, Kumar S, et al. Immunogenicity and
342 Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding
343 Domain Derivative. *ACS Infectious Diseases* (2021) 7(8):2546-64. doi:
344 10.1021/acsinfecdis.1c00276.

Neutralization of SARS-CoV-2 Omicron

- 345 9. Australian Government Department of Health. *Vaxzevria (AstraZeneca)* (2022). Available at:
346 <https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/approved->
347 [vaccines/astrazeneca](https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/approved-vaccines/astrazeneca)
- 348 10. Kärber G. Beitrag Zur Kollektiven Behandlung Pharmakologischer Reihenversuche. *Naunyn-*
349 *Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie* (1931) 162(4):480-
350 3. doi: 10.1007/BF01863914.
- 351 11. Sitaras I, Personal Communication (16 February 2022) to S.S. Vasana.
- 352 12. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly Accurate
353 Protein Structure Prediction with AlphaFold. *Nature* (2021) 596(7873):583-9. doi:
354 10.1038/s41586-021-03819-2.
- 355 13. Kuiper MJ, Wilson LOW, Mangalaganesh S, Lee C, Reti D, Vasana SS. “But Mouse, You Are
356 Not Alone”: On Some Severe Acute Respiratory Syndrome Coronavirus 2 Variants Infecting
357 Mice. *ILAR Journal* (2022). doi: 10.1093/ilar/ilab031.
- 358 14. Phillips JC, Hardy DJ, Maia JDC, Stone JE, Ribeiro JV, Bernardi RC, et al. Scalable
359 Molecular Dynamics on Cpu and Gpu Architectures with NAMD. *J Chem Phys* (2020)
360 153(4):044130. doi: 10.1063/5.0014475.
- 361 15. R-Core-Team. *R: A Language and Environment for Statistical Computing*; R Foundation for
362 Statistical Computing: Vienna, Austria, 2019. Available online: <https://www.r-project.org/>
- 363 16. César Muñoz-Fontela C, Widerspich L, Albrecht RA, Beer M, Carroll, MW, et al. Advances
364 and gaps in SARS-CoV-2 infection models. *PLoS Pathogens* (2022) 18(1): e1010161. doi:
365 10.1371/journal.ppat.1010161.
- 366 17. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic
367 Thrombocytopenia after ChAdOx1 NCoV-19 Vaccination. *New England Journal of Medicine*
368 (2021) 384(22):2092-101. doi: 10.1056/NEJMoa2104840.
- 369 18. Peterson-KFF Health System Tracker. *COVID-19 leading cause of death ranking* (2022).
370 Available at: <https://www.healthsystemtracker.org/>
- 371 19. Schmidt F, Muecksch F, Weisblum Y, Da Silva J, Bednarski E, Cho A, et al. Plasma
372 Neutralization of the SARS-CoV-2 Omicron Variant. *New England Journal of Medicine*
373 (2021) 386(6):599-601. doi: 10.1056/NEJMc2119641.
- 374 20. Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant
375 Neutralization in Serum from Vaccinated and Convalescent Persons. *New England Journal of*
376 *Medicine* (2022) 386(7):698-700. doi: 10.1056/NEJMc2119236.
- 377 21. Fratev F. R346k Mutation in the Mu Variant of SARS-CoV-2 Alters the Interactions with
378 Monoclonal Antibodies from Class 2: A Free Energy Perturbation Study. *Journal of*
379 *Chemical Information and Modeling* (2022) 62(3):627-31. doi: 10.1021/acs.jcim.1c01243.
- 380 22. CDC. *COVID Data Tracker* (2022). Available at: [https://covid.cdc.gov/covid-data-](https://covid.cdc.gov/covid-data-tracker/#datatracker-home)
381 [tracker/#datatracker-home](https://covid.cdc.gov/covid-data-tracker/#datatracker-home)
- 382 23. Hui KPY, Ho JCW, Cheung M-c, Ng K-c, Ching RHH, Lai K-l, et al. SARS-CoV-2 Omicron
383 Variant Replication in Human Bronchus and Lung Ex Vivo. *Nature* (2022). doi:
384 10.1038/s41586-022-04479-6.
- 385 24. Fischer H, Widdicombe JH. Mechanisms of Acid and Base Secretion by the Airway
386 Epithelium. *J Membr Biol* (2006) 211(3):139-50. Epub 20061107. doi: 10.1007/s00232-006-
387 0861-0.
- 388 25. Liu L, Iketani S, Guo Y, Chan JFW, Wang M, Liu L, et al. Striking Antibody Evasion
389 Manifested by the Omicron Variant of SARS-CoV-2. *Nature* (2021). doi: 10.1038/s41586-
390 021-04388-0.

Neutralization of SARS-CoV-2 Omicron


- 391 26. Zhao Z, Li H, Wu X, Zhong Y, Zhang K, Zhang YP, et al. Moderate Mutation Rate in the
392 SARS Coronavirus Genome and Its Implications. *BMC Evol Biol* (2004) 4:21. Epub
393 20040628. doi: 10.1186/1471-2148-4-21.
- 394 27. Bar-On YM, Flamholz A, Phillips R, Milo R. SARS-CoV-2 (Covid-19) by the Numbers.
395 *eLife* (2020) 9:e57309. doi: 10.7554/eLife.57309.
- 396 28. Sanjuán R, Nebot MR, Chirico N, Mansky LM, Belshaw R. Viral Mutation Rates. *J Virol*
397 (2010) 84(19):9733-48. Epub 20100721. doi: 10.1128/jvi.00694-10.
- 398 29. Bauer DC, Tay AP, Wilson LOW, Reti D, Hosking C, McAuley AJ, et al. Supporting
399 Pandemic Response Using Genomics and Bioinformatics: A Case Study on the Emergent
400 SARS-CoV-2 Outbreak. *Transbound Emerg Dis* (2020) 67(4):1453-62. doi:
401 <https://doi.org/10.1111/tbed.13588>.
- 402 30. Koyama T, Platt D, Parida L. Variant Analysis of SARS-CoV-2 Genomes. *Bull World Health*
403 *Organ* (2020) 98(7):495-504. Epub 2020/06/02. doi: 10.2471/BLT.20.253591.
- 404 31. Australian Government Department of Health. ATAGI statement on defining 'up-to-date'
405 status for COVID-19 vaccination (2022). Available at: [https://www.health.gov.au/news/atagi-](https://www.health.gov.au/news/atagi-statement-on-defining-up-to-date-status-for-covid-19-vaccination)
406 [statement-on-defining-up-to-date-status-for-covid-19-vaccination](https://www.health.gov.au/news/atagi-statement-on-defining-up-to-date-status-for-covid-19-vaccination)
- 407 32. Burki TK. Fourth Dose of Covid-19 Vaccines in Israel. *The Lancet Respiratory Medicine*
408 (2022) 10(2):e19. doi: 10.1016/S2213-2600(22)00010-8.
- 409 33. Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. 4th Dose
410 Covid mRNA Vaccines' Immunogenicity & Efficacy against Omicron VOC. *medRxiv*
411 (2022):2022.02.15.22270948. doi: 10.1101/2022.02.15.22270948.
- 412 34. Mandelboim M, Personal Communication (22 February 2022) to S.S. Vasan.
- 413 35. May DH, Rubin BER, Dalai SC, Patel K, Shafiani S, Elyanow R, et al. Immunosequencing
414 and Epitope Mapping Reveal Substantial Preservation of the T Cell Immune Response to
415 Omicron Generated by SARS-CoV-2 Vaccines. *medRxiv* (2021):2021.12.20.21267877. doi:
416 10.1101/2021.12.20.21267877.
- 417 36. Keeton R, Tincho MB, Ngomti A, Baguma R, Benede N, Suzuki A, et al. SARS-CoV-2 Spike
418 T Cell Responses Induced Upon Vaccination or Infection Remain Robust against Omicron.
419 *medRxiv* (2021):2021.12.26.21268380. doi: 10.1101/2021.12.26.21268380.
- 420 37. Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, et al.
421 Homologous and Heterologous COVID-19 Booster Vaccinations. *New England Journal of*
422 *Medicine* (2022). doi: 10.1056/NEJMoa2116414.
- 423 38. He Q, Mao Q, An C, Zhang J, Gao F, Bian L, et al. Heterologous Prime-Boost: Breaking the
424 Protective Immune Response Bottleneck of COVID-19 Vaccine Candidates. *Emerg Microbes*
425 *Infect* (2021) 10(1):629-37. doi: 10.1080/22221751.2021.1902245.
- 426 39. Jayaraman KS. Ferret Chosen as Animal Model to Test Coronavirus Vaccines. *Nature India*
427 (5 April 2020). Available at: <http://go.nature.com/39LGAqx>.
- 428 40. Marsh GA, McAuley AJ, Au GG, Riddell S, Layton D, Singanallur NB, et al. ChAdOx1
429 nCoV-19 (AZD1222) Vaccine Candidate Significantly Reduces SARS-CoV-2 Shedding in
430 Ferrets. *npj Vaccines* (2021) 6(1):67. doi: 10.1038/s41541-021-00315-6.
- 431 41. Van Doremalen N, Purushotham Jyothi N, Schulz J E, Holbrook M G, Bushmaker T,
432 Carmody A, et al. Intranasal ChAdOx1 nCov-19/AZD1222 Vaccination Reduces Viral
433 Shedding after SARS-CoV-2 D614G Challenge in Preclinical Models. *Science Translational*
434 *Medicine* (2021) 13(607):eabh0755. doi: 10.1126/scitranslmed.abh0755.
- 435 42. Imperial College London. *Landmark coronavirus study to trial inhaled Imperial and Oxford*
436 *vaccines* (2020). Available at: [https://www.imperial.ac.uk/news/203653/landmark-](https://www.imperial.ac.uk/news/203653/landmark-coronavirus-study-trial-inhaled-imperial/)
437 [coronavirus-study-trial-inhaled-imperial/](https://www.imperial.ac.uk/news/203653/landmark-coronavirus-study-trial-inhaled-imperial/)

Neutralization of SARS-CoV-2 Omicron

- 438 43. BBC. *AstraZeneca vaccine: Did nationalism spoil UK's 'gift to the world'?* (2022). Available
439 at: <https://www.bbc.com/news/health-60259302>
- 440 44. Huang, J. et al. CHARMM36m: an improved force field for folded and intrinsically
441 disordered proteins. *Nature Methods* (2017) 14, 71-73, doi:10.1038/nmeth.4067
- 442 45. Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
443 *Science* (2020) 367, 1260-1263 doi: 10.1126/science.abb2507
- 444 46. Watanabe Y, Allen, JD, Wrapp, J, McLellan, JS, Crispin, M. Site-specific glycan analysis of
445 the SARS-CoV-2 spike *Science* (2020) 369(6501):330-333. doi: 10.1126/science.abb9983.
- 446 47. Humphrey, W., Dalke, A. and Schulten, K., "VMD - Visual Molecular Dynamics", *J. Molec.*
447 *Graphics*, 1996, vol. 14, pp. 33-38.41

Neutralization of SARS-CoV-2 Omicron

448 **Figures 1-4**




449

450 **Figure 1: Box Plots Showing 50% Neutralisation Titres (NT₅₀) Against SARS-CoV-2 Variants**
451 **of Concern with Plasma from Human Volunteers**

452 Neutralisation of VIC31, Delta, and Omicron by human donor samples collected at different
453 timepoints following vaccination with AstraZeneca (A), Moderna (B), or Pfizer (C) COVID-19
454 vaccines. The bold horizontal line represents median titre, with the 1st and 3rd quartiles represented
455 by the box. Statistical analysis is provided in Supplementary Table S3.

Neutralization of SARS-CoV-2 Omicron



456

457 **Figure 2: Box Plots Showing 50% Neutralization Titres (NT₅₀) Against SARS-CoV-2 Variants**
 458 **of Concern Assessed by Sex of Donors**


459 Plasma samples from human volunteers vaccinated with either AstraZeneca (A), Moderna (B), or
 460 Pfizer (C) vaccines were tested in neutralisation assays against VIC31 (i), Delta (ii), and Omicron
 461 (iii), with titres assessed with respect to sex. The bold horizontal line represents median titre, with the

Neutralization of SARS-CoV-2 Omicron

462 1st and 3rd quartiles represented by the box. Statistical analysis is provided in Supplementary Table
463 S3.

Neutralization of SARS-CoV-2 Omicron

464




465

466 **Figure 3: Box Plots Showing NT₅₀ Values Against SARS-CoV-2 Variants of Concern Assessed**
 467 **by Age Group**

468 Plasma samples from human volunteers vaccinated with either AstraZeneca (A), Moderna (B), or
 469 Pfizer (C) vaccines were tested in neutralisation assays against VIC31 (i), Delta (ii), and Omicron
 470 (iii), with titres assessed with respect to age group. The bold horizontal line represents median titre,
 471 with the 1st and 3rd quartiles represented by the box. Statistical analysis is provided in
 472 Supplementary Table S3.

Neutralization of SARS-CoV-2 Omicron



473

474 **Figure 4: Structure of SARS-CoV-2 Spike Protein and Mutations of Interest**

475 **A.** The Omicron spike protein with mutations shown in pink. A single S1 domain is highlighted in
476 blue with the receptor binding domain (RBD) in the 'up' configuration is highlighted in cyan.

477 **B. & C.** Comparison of the RBD in the Omicron and Delta
478 variants, 15 mutations are observed in Omicron while only 2 in the Delta variant.

Neutralization of SARS-CoV-2 Omicron

479 **Tables 1 & 2**

480 **Table 1: Information on Human Participants, Vaccines, and Blood Collection Schedule**

		AstraZeneca	Moderna	Pfizer
Donor		n=6	n=12	n=15
Sex	Male	n=3	n=6	n=5
	Female	n=3	n=6	n=10*
Age [Median (Range)]	Male	58 (57-65)	41.5 (29-70)	31 (29-35)
	Female	57 (31-59)	38.5 (27-47)	33.5 (25-57)
	Overall	57.5 (31-65)	38.5(27-70)	33 (25-57)
Samples Used	pre-1 st Dose	n=6 (3M, 3F)	n=12 (6M, 6F)	n=15 (5M, 10F)
	2w Post-2 nd Dose	n=6 (3M, 3F)	n=12 (6M, 6F)	n=15 (5M, 10F)
	6mo Post-2 nd Dose			n=15 (5M, 10F)
	2w Post-3 rd Dose			n=14 (4M, 10F)

481 *For pre-1st dose and 2w Post-2nd dose the samples are gender balanced.

482

483 **Table 2: Sex-Based Mean and Standard Deviation for VNT Titres Against SARS-CoV-2**
 484 **Variants for Human Subjects Vaccinated with Different COVID-19 Vaccines.**

Vaccine	Sex	Estimates	VIC31				Delta				Omicron			
			1	2	3	4	1	2	3	4	1	2	3	4
AstraZeneca	Female	Mean	2.32	3.46	X	X	2.32	2.32	X	X	2.32	2.32	X	X
		SD	0.00	0.00	X	X	0.00	0.00	X	X	0.00	0.00	X	X
	Male	Mean	2.32	5.04	X	X	2.32	2.82	X	X	2.32	2.32	X	X
		SD	0.00	1.01	X	X	0.00	0.86	X	X	0.00	0.00	X	X
	All	Mean	2.32	4.25	X	X	2.32	2.57	X	X	2.32	2.32	X	X
		SD	0.00	1.08	X	X	0.00	0.61	X	X	0.00	0.00	X	X
Moderna	Female	Mean	2.32	7.16	X	X	2.32	5.99	X	X	2.32	2.57	X	X
		SD	0.00	1.11	X	X	0.00	0.76	X	X	0.00	0.61	X	X
	Male	Mean	2.32	6.93	X	X	2.32	5.05	X	X	2.32	2.82	X	X
		SD	0.00	1.17	X	X	0.00	1.28	X	X	0.00	0.80	X	X
	All	Mean	2.32	7.04	X	X	2.32	5.52	X	X	2.32	2.69	X	X
		SD	0.00	1.09	X	X	0.00	1.12	X	X	0.00	0.69	X	X
Pfizer	Female	Mean	2.32	7.22	3.75	8.93	2.32	6.36	3.37	7.39	2.32	2.73	2.32	5.95
		SD	0.00	1.08	0.66	1.07	0.00	1.04	0.79	0.82	0.00	0.67	0.00	1.22
	Male	Mean	2.32	6.76	4.61	9.32	2.32	5.76	4.34	8.82	2.32	2.49	2.32	6.07
		SD	0.00	0.92	0.71	0.64	0.00	1.06	0.97	1.09	0.00	0.38	0.00	1.43
	All	Mean	2.32	7.07	4.04	9.04	2.32	6.16	3.70	8.23	2.32	2.65	2.32	5.99
		SD	0.00	1.02	0.78	0.96	0.00	1.05	0.95	0.94	0.00	0.59	0.00	1.23

485 All VNT titres expressed as Log2 values. Values indicated as 2.32 represent titres below the assay detection limit. SD =
 486 Standard Deviation of Mean; 1 = pre-1st dose; 2 = 2wk Post-2nd dose; 3 = 6mo Post-2nd dose and 4 = 2wk Post-3rd dose. X
 487 = sample not available for analysis

488

489 **Data Availability Statement**

490 The original contributions presented in the study are included in the article/Supplementary Material.
491 Further inquiries can be directed to the corresponding author.

492 **Ethics Statement**

493 The study protocols were approved by institutional ethics committees of the Peter Doherty Institute,
494 Melbourne Australia [University of Melbourne Central Human Research Ethics Committee (2021-
495 21198-15398-3)] and the CSIRO (CSIRO Human Research Ethics Committee ID 2021_123_RR).
496 The reference serum for the neutralisation assay was derived from an animal study reviewed and
497 approved by CSIRO ACDP Animal Ethics Committee (AEC 2004).

498 **Author Contributions**

499 NBS designed the study with PJvV, AJM, SMG and SSV. PJvV and AJM performed the experiments
500 with NBS, MPB, SR and SG. NBS and SMG analysed the experimental data and provided statistical
501 interpretations, with inputs from PJvV, AJM, TWD and SSV. MJK performed biomolecular
502 modelling and provided structural interpretations. LC and JDD isolated the virus variants, which
503 were sequenced by KRB and MT. JAJ, SJK and AKW provided the human plasma samples and
504 obtained the necessary funding for the same. SM, SC and SSV analysed the health economic
505 implications. NBS, PJvV, AJM, MJK, SM, SC and SSV co-wrote the manuscript, and all authors
506 contributed to revisions and creation of the final version. SV conceived the project and
507 obtained funding.

508 **Funding**

509 This work was supported by funding (Principal Investigator: S.S.V.) from the CSIRO's Precision
510 Health & Responsible Innovation Future Science Platforms, National Health and Medical Research
511 Council (grant MRF2009092), and United States Food and Drug Administration (FDA) Medical
512 Countermeasures Initiative (contract 75F40121C00144). J.A.J., S.J.K. and A.K.W. are grateful to the
513 National Health and Medical Research Council (for grants GNT2002073, MRF2005544,
514 GNT1149990, fellowships and an investigator grant). We also thank the Victorian Government,
515 especially the Victorian Department of Health and Human Services, the major funder of the Victorian
516 Infectious Diseases Reference Laboratory and Barwon Health. The article reflects the views of the
517 authors and does not represent the views or policies of the funding agencies including the FDA.

518 **Conflict of Interest**

519 All claims expressed in this article are solely those of the authors and do not necessarily represent
520 those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any
521 product that may be evaluated in this article, or claim that may be made by its manufacturer, is not
522 guaranteed or endorsed by the publisher.

523 **Acknowledgments**

524 The authors are grateful for support from Professor Sharon Lewin, Professor Deborah Williamson
525 and colleagues at the Peter Doherty Institute for Infection and Immunity
526 (<https://www.grid.ac/institutes/grid.483778.7>); the CSIRO eHealth programme (particularly Drs
527 Laurence Wilson and Carol Lee); and the CSIRO's Australian Centre for Disease Preparedness

Neutralization of SARS-CoV-2 Omicron

528 (ACDP; <https://www.grid.ac/institutes/grid.413322.5>), especially Dr Daniel Layton and Kristen
529 McAuley. We thank Dr Amy Shurtleff of the Coalition for Epidemic Preparedness Innovations and
530 the University of Oxford's Professors Teresa Lambe and Dame Sarah Gilbert for access to positive
531 control ferret sera from their study (CSIRO ACDP Animal Ethics Committee Approval Reference:
532 AEC 2004).

Neutralization of SARS-CoV-2 Omicron

533 Supplementary Material

534 Supplementary Tables S1 to S3

535 Supplementary Table S1: Comparison for NT50 values on 2nd-2wk

Comparison	Variant	Estimate (‘adjusted’ p-value)
Pfizer vs Moderna	VIC31	p > 0.100
Pfizer vs Moderna	Omicron	p > 0.100
Pfizer vs Moderna	Delta	p > 0.100

536

537 Supplementary Table S2: One-way ANOVA results for vaccines, variants, sex, age and day 538 post vaccination/boosters

Vaccine	Variable	F-value	p-value	Tukey’s HSD post hoc Comparison (‘adjusted’ p-value)
Pfizer	Sex	0.002	>0.100	No significant difference
	Age	0.667	>0.100	No significant difference
	Day post vaccination/booster	119.9	<0.0001	Pre 1 st Dose – 2wk Post-2 nd Dose p < 0.0001 Pre 1 st Dose – 6mo Post-2 nd Dose p < 0.01 Pre 1 st Dose – 2wk Post-3 rd Dose p < 0.0001 2wk Post 2 nd Dose – 6mo Post-2 nd Dose p < 0.0001 2wk Post 2 nd Dose – 2wk Post-3 rd Dose p < 0.0001 6mo Post 2 nd Dose – 2wk Post-3 rd Dose p < 0.0001
	Variant	15.86	<0.0001	Delta – Omicron p < 0.0001 VIC31 – Omicron p < 0.0001
Moderna	Sex	0.104	>0.100	No significant difference
	Age	0.074	>0.100	No significant difference
	Day post vaccination/booster	64.56	<0.0001	Pre 1 st Dose – 2wk Post-2 nd Dose p < 0.0001
	Variant	8.839	<0.001	Delta – Omicron p < 0.05 VIC31 – Omicron p < 0.001
AstraZeneca	Sex	1.497	>0.100	No significant difference
	Age	1.401	>0.100	No significant difference
	Day post vaccination/booster	7.722	<0.01	Pre 1 st Dose – 2wk Post-2 nd Dose p < 0.01
	Variant	5.744	<0.01	VIC31 – Delta p < 0.05 VIC31 – Omicron p < 0.05

539

540

541

542

Neutralization of SARS-CoV-2 Omicron

543 **Supplementary Table S3: Two-way ANOVA results of interactions for vaccines, variants, sex,**
 544 **age and day post vaccination/boosters**

Vaccine	Factor 1	Factor 2	F-Value	p-Value	Tukey's HSD post hoc Comparison ('adjusted' p-value)
Pfizer	Variant	Sex	0.053	>0.100	No significant difference
		Age	0.018	>0.100	No significant difference
		Day post vaccination/booster	24.54	<0.0001 [†]	Pre 1 st Dose – 2wk Post-2 nd Dose p < 0.0001
					Pre 1 st Dose – 6mo Post-2 nd Dose p < 0.0001
					Pre 1 st Dose – 2wk Post-3 rd Dose p < 0.0001
					2wk Post 2 nd Dose – 6mo Post-2 nd Dose p < 0.0001
					2wk Post 2 nd Dose – 2wk Post-3 rd Dose p < 0.0001
					6mo Post 2 nd Dose – 2wk Post-3 rd Dose p < 0.0001
					Delta – Omicron p < 0.0001
					VIC31 – Omicron p < 0.0001
Moderna	Variant	Sex	0.158	>0.100	No significant difference
		Age	0.040	>0.100	No significant difference
		Day post vaccination/booster	59.91	<0.0001 [†]	Pre 1 st Dose – 2wk Post-2 nd Dose p < 0.0001 Delta – Omicron p < 0.05 VIC31 – Omicron p < 0.001
AstraZeneca	Variant	Sex	0.872	>0.100	No significant difference
		Age	0.507	>0.100	No significant difference
		Day post vaccination/booster	13.00	<0.0001 [†]	Pre 1 st Dose – 2wk Post-2 nd Dose p < 0.01
					Delta – Omicron p < 0.05 VIC31 – Omicron p < 0.05

545 [†]In two-way ANOVA the main effect for variant was statistically significant (p < 0.0001). However, the interaction
 546 effects of variant with age or sex were not statistically significant (p > 0.05) but there were statistically significant
 547 interactions between the effects of variant and day post vaccination/booster (p < 0.001).
 548
 549

550 **Supplementary Methods**

551

552 **Statistical analysis using linear mixed models**

553

554 Linear Mixed Models (*lm* and *lmer*) analyses were used to investigate the interactions of age,
555 sex, vaccine, and day post vaccination/booster with neutralising antibody titres to the three different
556 virus variants using ‘*lme4*’ library in R [15]. To avoid, over fitting of data, we are not showing the
557 results of *lm* and *lme* analyses. One-way and two-way ANOVA analyses showed that, for all
558 vaccines (Pfizer, Moderna and AstraZeneca), day post vaccination/booster and virus variant were the
559 main contributors to differences in neutralising antibody responses, while age and sex did not have
560 significant effects.

561

562 Linear Mixed Model analysis of the variance between variables (results not shown) confirmed
563 the ANOVA analyses which showed that day post vaccination/booster and virus variant are the major
564 contributors to titre differences, but further shows that there was a significant difference in
565 neutralising titres elicited by the three different vaccines, mostly due to poor responses to the
566 AstraZeneca vaccine. This analysis model further suggests that younger individuals (aged less than
567 35 years) are likely to have a stronger neutralising antibody response than older individuals, but we
568 concede that this finding might be confounded by the distribution of the ages within the vaccine
569 groups. This might also explain the poorer responses in the AstraZeneca group because of the
570 vaccine advice in Australia (AstraZeneca mostly used in the older age group).

571 **Modelling using *in silico* methods**

572 Molecular simulations were performed using NAMD2.14 with CHARM36m forcefield [44]
573 employing a TIP3 water model. The Spike model was based on the pdb structure 6VSB3 [45], built
574 with additions segments predicted with AlphaFold. The Spike protein only included residues 13 to
575 1160 (omitting transmembrane domain, to reduce the simulation size). Glycosylation of the Spike
576 protein was manually constructed using Visual Molecular Dynamics (VMD) guided by glycan
577 analysis [46]. Omicron models were constructed in two conformations, all RBD ‘down’, and 2 RBD
578 ‘down’ one RBD ‘up’. Both models included an ACE2 domain in the expected binding position.


579 Simulations were run with Periodic Boundary Conditions ‘PBCs’ using the NPT ensemble at
580 310K and 1 bar pressure employing Langevin dynamics. The PBCs were constant in the XY
581 dimensions. Long-range Coulomb forces were computed with the Particle Mesh Ewald method with
582 a grid spacing of 1 Å. 2 fs timesteps were used with non-bonded interactions calculated every 2 fs
583 and full electrostatics every 4 fs while hydrogens were constrained with the ‘SHAKE’ algorithm. The
584 cut-off distance was 12 Å with a switching distance of 10 Å and a pair-list distance of 14 Å. Pressure
585 was controlled to 1 atmosphere using the NoséHoover Langevin piston method employing a piston
586 period of 100 fs and a piston decay of 50 fs. Trajectory frames were captured every 100 ps.
587 Simulations were performed for at least 200 nanoseconds. Trajectories were visualized and analysed
588 using VMD [47].

589

590 **Supplementary Figures**

591

592



593

594


595

596

597 **Supplementary Figure S1.** a) Omicron spike protein binding to ACE2 domain (shown in yellow).
598 S1 domain shown in blues, with the receptor binding domain shown in cyan. Glycosylation is shown
599 as green sticks. b) close up of the ACE2 binding interface of Omicron spike RBD showing the
600 interaction of contacting residues.

601

Neutralization of SARS-CoV-2 Omicron



602

603 **Supplementary Figure S2.** Close up of Omicron mutations in adjacent receptor binding domains
604 (pink and blue) in ‘down’ position showing the close proximity of residues L371, P373 and F375 on
605 the blue domain to the adjacent H505. This complementary arrangement may have influence on the
606 RBD ‘up’/‘down’ transitions by pH dependant ionization of H505.

607